Thrombocytopenia after COVID-19 vaccination
Research output: Contribution to journal › Journal article › Research › peer-review
28,198 healthcare staff exposed to PfizerBioNTech/Moderna (N = 11,689) or Oxford-AstraZeneca (N = 16,509) COVID-19 vaccines.
•
50 (40 women and 10 men) had thrombocytopenia of 2,130 with post-vaccination platelets measured.
•
Among 1,873 women, 3.0% exposed to Oxford-AstraZeneca versus 1.5% to PfizerBioNTech/Moderna had thrombocytopenia.
•
This corresponds to an OR of 1.99 [95% CI 1.05–3.76]; among 257 men, the corresponding OR [95% CI] was 0.49 [0.14–1.79].
•
Severe thrombocytopenia (platelets <50 × 109/L) was seen among Oxford-AstraZeneca-exposed patients only (3 women age 50–60).
•
50 (40 women and 10 men) had thrombocytopenia of 2,130 with post-vaccination platelets measured.
•
Among 1,873 women, 3.0% exposed to Oxford-AstraZeneca versus 1.5% to PfizerBioNTech/Moderna had thrombocytopenia.
•
This corresponds to an OR of 1.99 [95% CI 1.05–3.76]; among 257 men, the corresponding OR [95% CI] was 0.49 [0.14–1.79].
•
Severe thrombocytopenia (platelets <50 × 109/L) was seen among Oxford-AstraZeneca-exposed patients only (3 women age 50–60).
Original language | English |
---|---|
Article number | 102712 |
Journal | Journal of Autoimmunity |
Volume | 123 |
Number of pages | 2 |
ISSN | 0896-8411 |
DOIs | |
Publication status | Published - 2021 |
Links
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8313538/pdf/main.pdf
Final published version
ID: 275767061